AstraZeneca's asthma drug succeeds late-stage study
Image Credit: shortpedia
AstraZeneca today said its asthma treatment for a chronic inflammatory disease of the nasal passage linings, or sinuses, met main goals in a late-stage study. The treatment, Fasenra, showed a statistically significant improvement in treating patients with severe bilateral nasal polyposis that were still symptomatic despite continued treatment with standard of care. Fasenra was effective in treating the size of nasal polyps.